Qingqing Zhou

Qingqing Zhou

Auto-generated profile, based on publicly available information

Qingqing Zhou

The First Affiliated Hospital, Yunnan Institute of Digestive Disease, Kunming Medical University, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Proceedings of the VLDB Endowment
Verified
Journal Article
Open access
XWXiaoying Wang
Xiaoying Wang
CQChangbo Qu
Changbo Qu
WWWeiyuan Wu
Weiyuan Wu
JWJiannan Wang
Jiannan Wang
QZQingqing Zhou
Qingqing Zhou
Cardinality estimation is a fundamental but long unresolved problem in query optimization. Recently, multiple papers from different research groups consistently report that learned models have the potential to replace existing cardinality estimators. In this paper, we ask a forward-thinking question: Are we ready to deploy these learned cardinality models in production? Our study consists of three main parts. Firstly, we focus on the static environment (i.e., no data updates) and compare five new learned methods with nine traditional methods on four real-world datasets under a unified workload setting. The results show that learned models are indeed more accurate than traditional methods, but they often suffer from high training and inference costs. Secondly, we explore whether these learned models are ready for dynamic environments (i.e., frequent data updates). We find that they cannot catch up with fast data updates and return large errors for different reasons. For less frequent updates, they can perform better but there is no clear winner among themselves. Thirdly, we take a deeper look into learned models and explore when they may go wrong. Our results show that the performance of learned methods can be greatly affected by the changes in correlation, skewness, or domain size. More importantly, their behaviors are much harder to interpret and often unpredictable. Based on these findings, we identify two promising research directions (control the cost of learned models and make learned models trustworthy) and suggest a number of research opportunities. We hope that our study can guide researchers and practitioners to work together to eventually push learned cardinality estimators into real database systems.

7 June 2021 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
QZQingqing Zhou
Qingqing Zhou
BXBingyao Xue
Bingyao Xue
RGRongcheng Gu
Rongcheng Gu
PLPing Li
Ping Li
QGQing Gu
Qing Gu

29 August 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MHMinshan Huang
Minshan Huang
HCHang Chen
Hang Chen
HWHUI WANG
HUI WANG
XWXianmei Wang
Xianmei Wang
DWDa Wang
Da Wang
LMLanqing Ma
Lanqing Ma
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly becoming a prevalent cause of hepatocellular carcinoma (HCC). Our study examines the burden of MASH-related HCC globally, regionally, and nationally, along with associated risk factors from 1990 to 2019, considering variables such as age, sex, and socioeconomic status.Objective: We aimed to report the global, regional, and national burden of liver cancer due to MASH and its attributable risk factors between 1990 and 2019, by age, sex, and sociodemographic index (SDI).Methods: Utilizing the Global Burden of Disease 2019 project, we analyzed data on prevalence, mortality, and disability-adjusted life years (DALYs) for liver cancer attributable to MASH across 204 countries. We provided counts and rates per 100,000 population, including 95% uncertainty intervals.Results: In 2019, there were 46.8 thousand cases of MASH-related HCC, leading to 34.7 thousand deaths, and 795.8 thousand DALYs globally. While the prevalence increased by 19.8% since 1990, the death and DALY rates decreased by 5.3% and 15.1%, respectively. The highest prevalence was in High-income Asia Pacific, with the greatest increases observed in Australasia, Central Asia, and High-income North America. Southern Sub-Saharan Africa reported the highest death rate, while the lowest rates were in parts of Latin America, Central Sub-Saharan Africa, and Eastern Europe. DALY rates were the highest in Southern Sub-Saharan Africa and the lowest in Tropical Latin America.Discussion: The burden of MASH-related HCC is expected to rise slightly over the next decade. This disease, which is not associated with the SDI, remains a major public health problem. In addition, the escalating rates of obesity, demographic shifts, and an aging population could position MASH as a leading factor in liver cancer cases, surpassing viral hepatitis. It is imperative, therefore, that the forthcoming years see the implementation of strategic interventions aimed at the early detection and prevention of liver cancer associated with MASH.

30 November 2022 in Current Opinion in Food Science
Verified
Journal Article
Closed access
YLYonglu Li
Yonglu Li
YWYadi Wang
Yadi Wang
PLPing Li
Ping Li
QZQingqing Zhou
Qingqing Zhou
Xiaodong ZhengXiaodong Zheng
Xiaodong Zheng
QGQing Gu
Qing Gu

1 December 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YSYunpeng Sun
Yunpeng Sun
QZQingqing Zhou
Qingqing Zhou
JLJunjian Li
Junjian Li
CZChang Zhao
Chang Zhao
ZYZhengping Yu
Zhengping Yu
QZQiandong Zhu
Qiandong Zhu
Objective: This study investigated the mechanism of RP11-422N16.3 sponging miR-23b-3p in cell proliferation, apoptosis and epithelial-mesenchymal transition (EMT) in liver cancer. Methods: Expressions of RP11-422N16.3, miR-23b-3p and dimethylglycine dehydrogenase (DMGDH) were determined in liver cancer tissues, adjacent normal tissues, hepatocellular carcinoma cell lines and normal liver epithelial cell line. Up-regulation of RP11-422N16.3 and down-regulation of miR-23b-3p were conducted in hepatocellular carcinoma cells. Bioinformatics analysis, luciferase reporter assay and RNA-pull down assay were performed to verify the relationship among miR-23b-3p, DMGDH, as well as RP11-422N16.3. Cell proliferation and cell apoptosis were determined by CCK-8 and Flow Cytometry analysis, respectively. Results: Expressions of RP11-422N16.3 and DMGDH were down-regulated while that of miR-23b-3p were up-regulated in hepatocellular carcinoma cancer tissues and cells. RP11-422N16.3 localized in cytoplasm and competitively bound to miR-23b-3p. Up-regulation of RP11-422N16.3 and down-regulation of miR-23b-3p contributed to increased expressions of DMGDH and E-cadherin, and decreased expressions of miR-23b-3p, ZEB1, Snail and Vimentin, resulting in inhibiting cell proliferation and promoting cell apoptosis. Inhibition of RP11-422N16.3 or overexpression of miR-23b-3p accelerated cell proliferation and slowed down cell apoptosis. miR-23b-3p inhibited the expression of DMGDH. Conclusion: Our data suggested that LncRNA RP11-422N16.3, by competitively binding to miR-23b-3p, promoted DMGDH expression, contributing to inhibit cell proliferation and EMT, and induce cell apoptosis in hepatocellular carcinoma cells.

2 May 2025 in Food Bioscience
Verified
Journal Article
Closed access
QZQingqing Zhou
Qingqing Zhou
YYYajun Yu
Yajun Yu
ZXZuorui Xie
Zuorui Xie
YZYingying Zhou
Yingying Zhou
YLYanan Li
Yanan Li
QGQing Gu
Qing Gu